EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II

Snezana Milanovic iD, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Yu-Luan Chen, Yongquan Lai, Manu Chakravarthy, Clay Dehn, Edward Jackson, Kenneth Koblan, Seth C Hopkins

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70110 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Snezana Milanovic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sumitomo Pharma America, Inc., Marlborough, Massachusetts, USA. Hauptthemen laut MEDLINE: Schizophrenia, Prediabetic State, Metabolic Syndrome, Antipsychotic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Antipsychotics increase metabolic syndrome ( MetSyn ) and diabetes risk. Preclinical and translational research data suggest that ulotaront, an investigational trace amine‐associated receptor 1 (TAAR1) agonist, may have beneficial metabolic effects. This Phase 1b study collected pilot data on 4‐week ulotaront exposure and weight‐associated metabolic markers. Materials and Methods A double‐blind, randomised, multiple‐dose within subject trial compared ulotaront to continued prior antipsychotic ( PA ) on metabolic markers in schizophrenia patients at high diabetes risk (presence of MetSyn and prediabetes). Metabolic characteristics of patients at check‐in were compared to a matched historical cohort without schizophrenia or antipsychotic exposure.

Results

When compared to PA , ulotaront treatment showed improvement trends for high glucose clamp, low glucose clamp, liver fat, liver fibro‐inflammation, back muscle fat infiltration, pancreas fat and pancreas volume. Visceral adipose tissue and weight changes favoured ulotaront treatment ( p < 0.001, p = 0.047). Liver fibro‐inflammation distinguished antipsychotic‐induced metabolic changes from the historical cohort ( p = 0.002).

Conclusions

Despite the sample size constraints due to early study termination, all key endpoint trends and statistically significant differences favoured ulotaront over previous antipsychotics, lending support that ulotaront may improve antipsychotic‐induced weight‐associated markers. Liver fibro‐inflammation may serve as a potential marker for antipsychotic‐induced MetSyn and prediabetes, and possible treatment target. Further research is needed to build on these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaPrediabetic StateMetabolic SyndromeAntipsychotic AgentsBody WeightHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultPilot Projects

Stichwörter der Autor:innen

beta cell functiondrug developmentdrug mechanismfatty liver diseasephases I and II study

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Sumitomo Pharma America, Inc., Marlborough, Massachusetts, USA.
  • Carmot Therapeutics, Berkley, California, USA.
  • Evolution Research Group, Edison, New Jersey, USA.
  • University of Jamestown, Jamestown, North Dakota, USA.
  • Perspectum Ltd., Oxford, UK.

ORCID-Profile: Snezana Milanovic

Zitieren

APA

Milanovic, S., Lew, R., Xiong, K., Casavant, E., Galluppi, G., Chen, Y. L., Lai, Y., Chakravarthy, M., Dehn, C., Jackson, E., Koblan, K., & Hopkins, S. C. (2026). A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70110

Vancouver

Milanovic S, Lew R, Xiong K, Casavant E, Galluppi G, Chen YL, et al. A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70110

BibTeX
@article{Milanovic2026,
  author = {Milanovic, Snezana and Lew, Robert and Xiong, Kuangnan and Casavant, Emily and Galluppi, Gerard and Chen, Yu-Luan and Lai, Yongquan and Chakravarthy, Manu and Dehn, Clay and Jackson, Edward and Koblan, Kenneth and Hopkins, Seth C},
  title = {A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70110}
}
Kostenlos starten →